Company InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.301 ^USD	+0.33%		-10.15%	-27.64%

Apr. 04	InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease	CI
Feb. 13	InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs	CI

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.

Number of employees: 13

USD in Million	2022	Weight	2023	Weight	Delta
BayMedica 100.0 %	1	100.0 %	4	100.0 %	+279.61%

USD in Million	2022	Weight	2023	Weight	Delta
Canada 100.0 %	1	100.0 %	4	100.0 %	+279.61%

Managers	Title	Age	Since
Eric Adams CEO	Chief Executive Officer	61	16-06-15
Michael Woudenberg COO	Chief Operating Officer	-	18-11-04
Colin Clancy IRC	Investor Relations Contact	-	-
Gerard Griffin SAM	Sales & Marketing	-	22-01-31
Eric Hsu PRN	Corporate Officer/Principal	-	18-03-12
Alexandra Mancini LAW	General Counsel	-	-

Members of the board	Title	Age	Since
Janet Grove BRD	Director/Board Member	57	22-02-10
Eric Adams CEO	Chief Executive Officer	61	16-06-15
Andrew Hull CHM	Chairman	61	16-09-11
Bryan Baldasare BRD	Director/Board Member	58	22-05-11
Nicole Lemerond BRD	Director/Board Member	49	22-08-07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,056,970	5,974,441 ( 98.64 %)	0	98.64 %

Name	Equities	%	Valuation
Sabby Management LLC 8.452 %	511,934	8.452 %	186 344 $
Armistice Capital LLC 3.401 %	205,968	3.401 %	74 972 $
Eric Adams 0.7258 %	43,959	0.7258 %	16 001 $
Renaissance Technologies LLC 0.6422 %	38,900	0.6422 %	14 160 $
Andrew Hull 0.6316 %	38,258	0.6316 %	13 926 $
Citadel Securities GP LLC 0.5615 %	34,009	0.5615 %	12 379 $
Two Sigma Securities LLC 0.2129 %	12,894	0.2129 %	4 693 $
Shane Aaron Johnson 0.2012 %	12,184	0.2012 %	4 435 $
Alexandra Mancini 0.003962 %	240	0.003962 %	87 $
Qube Research & Technologies Ltd. (France) 0.003302 %	200	0.003302 %	73 $

InMed Pharmaceuticals, Inc.

815 West Hastings Street Suite 310

V6C 1B4, Vancouver

+604 669 7207

http://www.inmedpharma.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INMED PHARMACEUTICALS INC.	-27.64%	1.82M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.35%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.31%	16.81B
BEIGENE, LTD.	-26.84%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.4B
SAREPTA THERAPEUTICS, INC.	+20.86%	11.06B

Bio Therapeutic Drugs